46,362 Shares in Jazz Pharmaceuticals PLC $JAZZ Purchased by SEB Asset Management AB

SEB Asset Management AB acquired a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the first quarter, according to its most recent 13F filing with the SEC. The fund acquired 46,362 shares of the specialty pharmaceutical company’s stock, valued at approximately $8,765,000.

Other institutional investors have also added to or reduced their stakes in the company. LRI Investments LLC bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $38,000. Leonteq Securities AG bought a new position in Jazz Pharmaceuticals in the 4th quarter worth approximately $50,000. Root Financial Partners LLC grew its stake in Jazz Pharmaceuticals by 42.8% in the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock valued at $56,000 after buying an additional 89 shares in the last quarter. Danske Bank A S purchased a new position in Jazz Pharmaceuticals in the 3rd quarter valued at approximately $40,000. Finally, Caitong International Asset Management Co. Ltd raised its holdings in Jazz Pharmaceuticals by 1,383.3% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 332 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Truist Financial dropped their target price on Jazz Pharmaceuticals from $256.00 to $254.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Morgan Stanley reiterated an “overweight” rating and issued a $245.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, May 7th. Bank of America boosted their price objective on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. Weiss Ratings raised Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, June 29th. Finally, Raymond James Financial restated an “outperform” rating and issued a $239.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $259.06.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $254.22 on Wednesday. Jazz Pharmaceuticals PLC has a 1 year low of $105.00 and a 1 year high of $255.20. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. The stock has a market capitalization of $15.97 billion, a PE ratio of -12,704.65, a P/E/G ratio of 0.21 and a beta of 0.32. The company’s 50 day simple moving average is $236.03 and its two-hundred day simple moving average is $201.74.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The firm had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. Analysts predict that Jazz Pharmaceuticals PLC will post 21.9 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Heather Ann Mcsharry sold 2,000 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $241.00, for a total transaction of $482,000.00. Following the completion of the transaction, the director directly owned 18,449 shares in the company, valued at $4,446,209. The trade was a 9.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bruce C. Cozadd sold 6,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $240.47, for a total value of $1,442,820.00. Following the completion of the transaction, the director owned 366,682 shares in the company, valued at $88,176,020.54. This represents a 1.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,098 shares of company stock valued at $3,131,906 in the last ninety days. 4.10% of the stock is currently owned by corporate insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.